Blog Read the latest perspectives from our team of subject matter experts and others How H1 Integrates with Your CRM of ChoiceAt H1, we know that every life sciences organization has unique needs when it comes to customer relationship management (CRM). Some companies rely on long-established platforms, while others are adopting… Continue reading → Read the article Post Topics:Artificial Intelligence Commercialization Drug Development Global Impact KOL Engagement Patient Representation Provider Data Post Industries:Digital Health Health Plans Pharmaceutical & Biotechnology Artificial IntelligenceKOL EngagementProvider DataA Holistic Approach to Measuring ImpactMedical Affairs plays an essential role in evidence-based medicine, disease education, and driving better outcomes. Their knowledge is crucial as medications become more specialized and complex. They enable healthcare… Continue reading → Read the articleno Artificial IntelligenceCommercializationDrug DevelopmentKOL EngagementPatient RepresentationTrials & Data – H1’s Top 5 Diagnoses (Predictions) for 2024How will AI impact clinical trials? Will FDA legislation improve diversity? What platforms will key opinion leaders adopt? Every year, we take a look at annual predictions to help life… Continue reading → Read the articleno Artificial IntelligenceCommercializationDrug DevelopmentSix Possible Implications of Biden’s Executive Order on AI for Life SciencesThe life sciences sector stands on the brink of a new era marked by the confluence of artificial intelligence (AI) and biomedicine. With President Biden’s recent Executive Order on AI,… Continue reading → Read the articleno Drug DevelopmentPatient RepresentationWhy Clinical Trial Success Criteria Matters: 5 Essential QuestionsAs the pharmaceutical and biotech industries continue to push for faster drug development, the importance of inclusive clinical trial recruitment cannot be overlooked. With the rise of digital health and… Continue reading → Read the articleno Drug DevelopmentPatient RepresentationOptimizing Clinical Data Registries: Opportunities for Inclusion and FeasibilityIn an October 2023 report, BMC Medicine completed a follow-up on a 10-year effort to understand, report on and track data sharing challenges with big pharma, specifically for clinical… Continue reading → Read the articleno Artificial IntelligenceEvaluating an AI Product in Life SciencesThe life sciences industry, characterized by stringent regulations, vast data sets, and the critical nature of its decisions, is increasingly turning to Artificial Intelligence (AI) for solutions. AI has the… Continue reading → Read the articleno‹123456›»
